NVCR
NovoCure Limited12.93
-0.04-0.31%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Guidance buckets, Pax sales reuse
Q&A unpacked 2026 revenue guidance into low-to-mid single-digit GBM growth from established markets, modest ramps in new ones like Spain and Czechia, and $15-25M from Optune Lua and Pax. Management pushed back on GBM conservatism fears, insisting mid-single digits remain feasible with penetration under 40%. Optune Pax details emerged: reusing the torso sales force sans new hires, but payer coverage lags of 1-2 years ahead, just like lung. They're eyeing NCCN inclusion to unlock revenue. No walk-backs; answers reinforced prepared optimism. Investors watch Pax reimbursement traction. Steady path to EBITDA breakeven.
Key Stats
Market Cap
1.45BP/E (TTM)
-Basic EPS (TTM)
-1.61Dividend Yield
0%Recent Filings
8-K
PANOVA-4 hits DCR endpoint
Novocure announced positive Phase 2 PANOVA-4 topline results on March 26, 2026, showing TTFields therapy with atezolizumab and gem/nab-pac boosted disease control rate to 74.4% in 78 mPDAC patients, versus 48% in historical controls—a 26.4% leap (p<0.05). Secondary metrics hit 34.6% ORR and 9.7-month median OS. Therapy proved well-tolerated. Full data awaits future forums.
10-K
FY2025 results
NovoCure posted FY2025 net revenues of $655M, up 8% y/y, driven by 10% active patient growth to 4,620—led by Optune Gio in France (+19%) and Germany (+11%)—while U.S. dipped on prior-period claim normalization. Q4 momentum shone through 7,035 total prescriptions, a record, with Optune Lua adding 545 amid NSCLC ramp-up, though gross margins slipped to 75% from array costs, tariffs, and Lua provisioning. R&D climbed 7% to $225M on LUNAR-2/KEYNOTE D58 acceleration, yet sales/marketing held flat and G&A fell 6% via equity efficiencies; Adjusted EBITDA narrowed to -$34M. Cash burned to $448M post-$561M note repayment, offset by $200M term loan, with $196M NOLs. METIS PMA advances brain mets hopes, but reimbursement delays for new indications risk quarterly uptake.
8-K
Q4 revenues up 8%, Pax approved
NovoCure posted full-year 2025 net revenues of $655.4 million, up 8% year-over-year, with Q4 at $174.4 million on rising active patients totaling 4,620 globally. FDA approved Optune Pax for locally advanced pancreatic cancer in February 2026, fueling expansion beyond GBM. Cash sits at $447.7 million; 2026 revenue guidance spans $675-$705 million. CMS billing hiccup resolved without revenue hit.
8-K
CMS revokes, then reinstates billing
NovoCure's U.S. subsidiary faced CMS revocation of Medicare billing privileges on February 2, 2026, retroactive to December 17, 2025, over an administrative re-validation glitch—not a substantive lapse. CMS rescinded it February 24, reinstating privileges retroactively. Services continued uninterrupted. No revenue impact expected.
8-K
FDA approves Optune Pax
FDA approved NovoCure's Optune Pax on February 11, 2026, for locally advanced pancreatic cancer with gemcitabine and nab-paclitaxel—the first in nearly 30 years. Phase 3 PANOVA-3 showed statistically significant mOS gains: 16.2 vs 14.2 months in ITT, plus 6.1-month extension in time to pain progression. Optune Pax expands NovoCure's Tumor Treating Fields platform. No new safety signals emerged.
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
ICCM
IceCure Medical Ltd.
0.63-0.01
LIVN
LivaNova PLC
63.08+0.02
NAOV
NanoVibronix, Inc.
4.02-0.29
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NNOX
NANO-X IMAGING LTD
3.21-0.03
NPCE
Neuropace, Inc.
15.88-0.04
NVNO
enVVeno Medical Corporation
0.32+0.01
SNWV
SANUWAVE Health, Inc.
31.46-0.18
VYCO
Vycor Medical, Inc.
0.16+0.00